Skip to main content
. 2017 Sep 7;77(15):1468–1477. doi: 10.1002/pros.23407

Figure 3.

Figure 3

Kaplan‐Meier survival analysis showing cumulative cancer specific survival of patients with either high or low CD169 score. Patients with low CD169 score had a significantly shorter survival time than patients with high CD169 score, P = 0.002, log‐rank test